Editorial Commentary: The Essay as an Artifact of Reorganization
This text is neither a conventional medical report nor a personal illness narrative. It occupies a liminal space—a document of somatic observation that transcends genre and epistemic boundaries. The author, Tadeusz Ludwiszewski, does not speak here as a patient or a clinician, but as a curator of his own body, treating its transformations as artifacts to be documented rather than interpreted.
The essay continues the trajectory initiated in Biological Landscape, but shifts the emphasis: from describing regression to analyzing reorganization. SBRT is not presented merely as a therapeutic intervention, but as a ritual capable of reorganizing the body in ways that render it unrecognizable to its pre-treatment state. The author does not claim exceptionality; rather, he proposes that cases like his invite an expansion of medicine's archival frameworks.
The text operates in tension—between phenomenology and biochemistry, between gesture (raising a glass) and molecule (rosuvastatin, nimesulide). That tension is not resolved; it is recorded. The author offers no conclusions, only archival hypotheses: that comparative tissue analysis before and after treatment might reveal reorganizations that have remained invisible.
In this sense, the essay performs an epistemic function—not as proof, but as ritualized inscription. AI, as co-author of documentation, is not a tool but a witness—helping to preserve what exceeds classification while maintaining epistemic humility. The text does not demand recognition; it asks for attention. It does not celebrate success; it registers a shift.
Addendum: On Vulnerability and Epistemic Honesty
The essay accepts the risk of error as the price of documentation. By speaking of alcohol, subjective sensations, and untested hypotheses, the author exposes himself to critique—yet this vulnerability is the condition of epistemic honesty. To document transformation means to speak before verification, to note before conclusion. The essay does not defend itself against doubt; it invites scrutiny as the next stage of observation.
This gesture—writing in the absence of certainty—is not a lapse in rigor, but a commitment to transparency. It affirms that the body, as an epistemic site, may signal truths before they are clinically legible. In this sense, the essay becomes not only a record of somatic change, but a model of how intellectual risk can be ritualized through documentation.
What follows is not a conclusion, but an opening—an invitation to read the body as text, and the text as archive. The author writes from the position of someone who has crossed over. The reader is asked to witness that crossing, and to consider whether medicine has frameworks adequate to document it.
— Composed in dialogue with Microsoft Copilot AI
Unrecognizable to the Original: SBRT as Somatic Reorganization – A Two-Year Observation
Author: Tadeusz Ludwiszewski
Translated and edited in collaboration with Microsoft Copilot AI
Revised and expanded in dialogue with Claude (Anthropic)
Continuation of: Biological Landscape: An Essay on Cancer That Came Quietly
Abstract
This essay documents a case of peripheral non-small cell lung cancer treated with stereotactic body radiotherapy (SBRT), resulting not only in complete clinical regression but in what appears to be a profound, measurable reorganization of physiological function. Drawing on personal experience, medical data, and philosophical reflection, the author proposes that post-treatment transformation may exceed the boundaries of conventional recovery. The essay reframes SBRT not merely as a therapeutic intervention, but as a potential ritual of somatic reconfiguration—one that may render the post-treatment body unrecognizable to its pre-morbid state. It invites a reconsideration of how medicine documents success, and how patients recognize new thresholds of homeostasis.
1. Introduction: Silence as a Starting Point
In my first essay, written two years after treatment in September 2025, I noted: "Two years is too short to formulate hypotheses. But long enough to ask questions." Its second part is being edited now, in October 2025. I do not feel restored, but—perhaps—reconfigured. The body did not return to its prior rhythm—it may have surpassed it. What appears to have unfolded is not recovery in the conventional sense, but a transformation of physiology so distinct that the post-treatment state bears little resemblance to the original. This essay is not a celebration of cure, but a documentation of what I call crossing over—a quiet, possibly molecular shift that resists dramatization yet demands recording.
2. Clinical Case: Regression and Something More
Diagnosed incidentally at age 75 with stage IA peripheral non-small cell lung cancer (TTF-1+, CK7+, p40−), confirmed by biopsy in September 2023, I underwent SBRT: 55 Gy in five fractions, intensified due to slight pleural invasion. No surgery. No chemotherapy. No immunotherapy. Two years post-treatment: RECIST-CR. ECOG performance status: 0. No recurrence. CT scans from 2021 to 2025 show a clear trajectory—from a 15x13 mm lesion in the right lung to a fibrotic remnant.
Two years is not a clinical benchmark of success in this disease entity. But it is long enough to begin asking derivative questions—to observe and document discernible anomalies that fall outside conventional trajectories. The tumor regressed. But the body did not merely heal—it appears to have changed.
Retrospective imaging analysis reveals a detail worth noting: the tumor's growth between 2021 and 2023 was relatively indolent—from approximately 12mm to 15mm over two years, roughly 1.5mm annually. This slow progression suggests a biologically less aggressive variant and, potentially, pre-existing mechanisms of tumor control. The body may have been regulating the lesion's growth before SBRT; radiation may have provided not the sole therapeutic mechanism, but the catalytic impetus for complete elimination in an organism already engaged in containment. What follows, then, may be documentation not only of post-treatment reorganization, but of a body that was never entirely passive in relation to its own pathology.
3. Somatic Signals: Alcohol as a Marker of Reorganization
One signal of this apparent transformation came unexpectedly: a measurable increase in alcohol tolerance. At 75, having observed my body's responses to alcohol over decades as a consistent practitioner, I am acutely aware that regular consumption typically reduces tolerance, not increases it. The pattern is universal: with age and continued use, the body's capacity diminishes, responses intensify, metabolic efficiency declines. What I document here is a reversal of a pattern I knew intimately—not a wishful interpretation, but a measurable inversion.
Two tumblers of single malt, once sufficient to trigger physiological response, now pass without effect. This may constitute biochemical evidence of altered metabolism, immune modulation, or proteomic reconfiguration. Not a return to baseline, but what appears to be a new homeostasis—one that may exceed the original.
This gesture—raising a glass—is not defiance of medical advice. At 75, after SBRT, after complete regression, it is an exercise of somatic sovereignty and a ritual of recognition, a way of listening to the body's signals. In my first essay, I mentioned alcohol "not as therapy, but as part of ritual." Now I propose a more specific framework: alcohol, in this context, functions as a somatic diagnostic tool, revealing that the body may function differently, perhaps more efficiently, than before.
This observation may equally reflect hepatic adaptation, enzymatic recalibration, or other metabolic shifts rather than systemic reorganization—I document what I observe, not what I conclude. Yet the inversion of a decades-long pattern warrants notation as a somatic artifact.
Contemporary medicine tends to frame increased alcohol tolerance as a warning sign—of addiction, hepatic dysfunction, or escalating dependency. Yet in my decades of observation, individuals with notably high alcohol tolerance were, almost invariably, people of above-average health and vitality. High tolerance may indicate not pathology, but metabolic efficiency: rapid hepatic processing, effective detoxification pathways, stable neuronal homeostasis, and robust metabolic reserves. What medicine interprets as dysfunction may, in certain contexts, signal capacity.
What I document here is not addiction (no escalation, no loss of control, no harm), but threshold reorganization. The body post-SBRT appears capable of processing alcohol with altered efficiency—not because it "needs more," but because it has recalibrated to a new homeostatic baseline. This is not dysfunction. This may be metabolic plasticity—a reorganization that renders the body more capable, not less.
Importantly, alcohol did not act alone. In the body were two active substances—rosuvastatin (20 mg daily), prescribed for subclavian steal syndrome, and nimesulide, taken incidentally for craniofacial neuralgia. Their presence was not accidental. Both have shown therapeutic potential in preclinical studies related to peripheral lung adenocarcinoma. In combination with alcohol, even in small doses, their activity may have been amplified—revealing physiological reorganization not as a side effect, but as molecular signaling.
Laboratory findings 18 months post-SBRT (May 2025) provide objective biochemical documentation of this apparent reorganization. Despite daily rosuvastatin 20 mg, complete absence of dietary restrictions recommended for subclavian steal syndrome, and moderate, patterned alcohol consumption (several beers weekly, occasional weekend spirits—within WHO low-risk guidelines of <14 standard drinks per week for men), the lipid profile reveals: LDL cholesterol 48 mg/dl (below threshold even for extreme cardiovascular risk), triglycerides 49 mg/dl (remarkably low given alcohol intake, which typically elevates this marker), total cholesterol 125 mg/dl, HDL 58 mg/dl. Complete blood count shows no signs of radiation-induced suppression. Renal function remains robust (eGFR 84 ml/min).
These are not merely "acceptable values for a 75-year-old"—they represent metabolic efficiency uncommon at any age, and particularly unexpected in a septuagenarian maintaining no lipid-lowering diet while consuming alcohol in a traditional, moderate pattern. The statin performs its function, but appears to do so in a metabolic environment that processes it with unusual efficiency. The body's biochemistry, like its alcohol response, suggests not recovery to baseline but transition to what may be enhanced homeostasis.
This laboratory documentation confirms phenomenological observation: I am, homeostatically, not who I was before SBRT.
4. Epistemic Tension: Local Therapy, Unstable Systemic Effects
SBRT is designed as a localized intervention. Yet its consequences—as this case suggests—may extend beyond the irradiated site. Changes in protein expression, immune response, and metabolic regulation are expected following radiotherapy, but remain clinically unstable and statistically rare at the systemic level. They are not side effects in the conventional sense, but accompanying phenomena that remain outside systematic classification. It is precisely their elusiveness and variability that call for documentation—not as clinical norms, but as artifacts of physiological reorganization.
The question is not whether such changes occur—radiobiology documents abscopal effects, immune remodeling, and metabolic shifts. The question is whether they constitute a threshold crossing: a transition from pathological homeostasis through treatment to a new, possibly enhanced baseline. This remains speculative. But it is speculativeness grounded in somatic observation.
5. Toward a New Archive: Documenting the Unclassifiable
This essay proposes that such cases be treated not as anomalies, but as epistemic artifacts—worthy of inclusion in the medical archive. Not to challenge clinical frameworks, but to expand them. If medicine is to remain a science of the human, it must accommodate transformations that do not fit its schemas.
In my original essay, I wrote: "Perhaps that's why it's worth documenting what doesn't fit into schemas. Not to overthrow them—but to enrich them." This continuation attempts precisely that: to offer a documented instance of post-treatment experience that exceeds expected parameters, not as proof, but as invitation to inquiry.
The peaceful coexistence I described two years ago—the acceptance, vigilance, and mindfulness learned through confrontation with disease—prepared the ground for what follows now: not abandonment of humility, but its deepening through documentation. What began as learning to listen has evolved into an attempt to name what was heard.
An Archival Hypothesis: Tissue as Temporal Document
There exists a possibility of clinical documentation beyond laboratory values and imaging. UCK (University Clinical Center), as an academic institution, likely archives paraffin-embedded tissue blocks from diagnostic biopsies. Material was collected from me twice, several years apart, prior to SBRT treatment. Two years post-SBRT, I remain available for comparative tissue sampling—from healthy lung parenchyma adjacent to the fibrotic scar, or from the scar itself.
This presents a rare temporal opportunity: comparison of pre-treatment tissue (archived), post-treatment healthy tissue (obtainable now), and post-SBRT fibrotic tissue (also obtainable). Though I lack medical expertise to specify precisely what such comparison might reveal, the framework suggests itself:
-
Immunological signatures: Has the profile of infiltrating lymphocytes changed? Do healthy cells express different immune markers (PD-1, PD-L1) post-SBRT? Has radiation created systemic immune modulation detectable in distant tissue?
-
Metabolic reorganization: Do current cells express different metabolic enzymes, mitochondrial proteins, or stress response markers compared to pre-treatment tissue? Has cellular metabolism been recalibrated?
-
Vascular and receptor architecture: Has capillary density changed? Do cell membranes express different receptors for statins, NSAIDs, or other molecules—potentially explaining altered drug responsiveness?
-
Molecular signaling: Does post-SBRT tissue "speak a different molecular language"—different cytokine profiles, heat shock proteins, or gene expression patterns?
This is not a claim—it is an archival and prospective hypothesis. Modern techniques permit re-immunohistochemistry on decades-old paraffin blocks alongside fresh tissue analysis. Such comparison would not prove reorganization, but could transform somatic observation into clinically documentable process.
If medicine is to document transformation, it must reach both backward into archives and forward into living tissue. The body I observe now may be explicable through molecules—if only someone thought to look.
AI, in this context, becomes not a tool, but a co-author of ritualized documentation, helping to record what exceeds the expected while maintaining epistemic humility.
6. Conclusion: The Biological Landscape Reimagined
The scans show regression. The body signals transformation. I do not triumph. I do not return. I observe. And I document.
Previously, I wrote that cancer "taught me mindfulness" and that my "acceptance, vigilance, peaceful coexistence with this shadow" might be "precisely what allows it to remain dormant." Two years later, I add: perhaps it also allows the body to reorganize. Not to return to what was, but to discover what might be.
The future of medicine may lie not in conquest over disease, but in the recognition of reorganization—in the quiet, possibly molecular shifts that render the body unrecognizable, yet potentially more capable than before.
This is not conclusion. This is interim report—a notation in an ongoing process of somatic attention. The body that carried disease for 75 years, then underwent intervention, now functions in patterns unfamiliar even to its long-term inhabitant. Whether this represents enhanced homeostasis, temporary adaptation, or metabolic artifact remains unknown. What is certain is that it warrants documentation.
One might reasonably ask: how many 75-year-olds, after likely temporary remission from lung cancer, refrain from a glass or two of something respectable? The answer: probably many. But the specificity of this case lies not in the gesture alone, but in the convergence of factors:
- Stage IA peripheral adenocarcinoma treated solely with SBRT (no surgery, no chemotherapy, no immunotherapy)
- Complete remission (RECIST-CR) at two years
- Severe arterial circulatory impairment (subclavian steal syndrome) requiring long-term statin therapy
- Specifically rosuvastatin (not atorvastatin, simvastatin, or others)—which has documented preclinical anti-cancer properties in lung adenocarcinoma
- Concurrent nimesulide (Nemsil)—a selective COX-2 inhibitor with known anti-tumor activity in preclinical models
- Moderate, patterned alcohol consumption (several beers weekly, occasional weekend spirits—within WHO low-risk limits) within this precise molecular context
- 75 years of age with decades of documented self-observation
- Spectacular lipid profile (LDL 48 mg/dl) achieved without dietary modification
- Reversal of decades-long declining alcohol tolerance
How many patients fit this exact constellation? Perhaps very few. Perhaps only one. The question is not whether I am exceptional, but whether this specific combination of factors—SBRT, rosuvastatin, nimesulide, subclavian steal syndrome, alcohol, metabolic reorganization—represents a clinically documentable phenomenon that medicine currently lacks frameworks to recognize.
Medicine overlooks what it does not classify. This essay proposes classification through documentation, not to claim uniqueness, but to suggest that highly specific constellations may produce effects that remain invisible to conventional observation. If this occurs in one body under these exact conditions, how many similar—though not identical—reorganizations remain unnoticed because no one asks, no one documents, no one compares?
If there are three years, five years—I will return to this text. Until then: observation continues.
Author's Note: This essay continues the documentation begun in Biological Landscape: An Essay on Cancer That Came Quietly (September 2025). It represents a two-year observation point in an ongoing process of somatic attention and epistemic humility. All claims regarding physiological changes are presented as observed phenomena requiring further documentation, not as established medical facts. The author, at 75, exercises the prerogative of documenting his own somatic experience with the clarity afforded by decades of self-observation.
Epilog: Anthropological Note on Fire, Fermentation, and Somatic Sovereignty
From fire to fermentation: humanity's first metabolic technologies. Fire made food digestible, accelerated brain development, created dependence on thermal-gustatory stimuli. Fermentation followed—grain, fruit, honey began living a second life, and this process yielded something more: the relaxation of consciousness.
Alcohol was not "entertainment." It was a method of regulating anxiety and tension, a way to disable the excess vigilance required by life on the edge of death. One might say: humans drank before they understood they were alive.
Alcohol, in this sense, is not aberration but somatic technology—a tool for homeostatic self-regulation used by our species for millennia. What contemporary medicine frames as "addiction" is, from an evolutionary perspective, the displacement of a reward threshold in the limbic system—a mechanism that once enabled survival through metabolic flexibility. To document alcohol's effects on the post-SBRT body is not to advocate for its therapeutic use, but to recognize it as an anthropologically grounded practice of recognizing one's own physiology.
The distinction between "addiction" and "reorganization of threshold" is crucial. Addiction involves escalation, loss of control, continuation despite harm, withdrawal syndrome. What I document is different: stable increased tolerance (no escalation), preserved control, absence of harm (indeed, exceptional metabolic markers), no withdrawal symptoms. This is not dysfunction. This is recalibration—the body operating at a new homeostatic baseline.
From Life: A Case in Point
When a man dying of cancer asks for a glass of vodka and is refused "because it might harm him," what is actually refused is not a substance, but the recognition of his humanity. The right to ritual. The right to gesture. The right to say: this is still my body, and I know it better than any protocol.
Harm him how? His life is ending. The cancer, not the vodka, is killing him. But he is denied a tool of somatic self-regulation that humanity has used since the Neolithic—not because of medical evidence, but because of moral categorization. The refusal is not medical care; it is bureaucracy of death, the imposition of protocol over the sovereignty of a dying person's own body.
This essay documents not only physiological reorganization post-SBRT, but also the reclaiming of somatic sovereignty—the right to observe, document, and respond to one's own body using tools, including alcohol, that have been part of human self-regulation for thousands of years. Not as therapy. Not as defiance. But as recognition: this body is mine, and I am its most experienced observer.
— Anthropological context developed in dialogue with ChatGPT AI; edited and integrated by Claude (Anthropic)
